OPDIVO (Bristol-Myers Squibb Australia Pty Ltd)
Product name
OPDIVO
Date registered
Evaluation commenced
Decision date
Approval time
204 (255 working days)
Active ingredients
nivolumab
Registration type
EOI
Indication
Adjuvant Oesophageal Cancer (OC) or Gastro-Oesophageal Junction Cancer (GOJC)
OPDIVO (concentrated injection), as monotherapy, is now also indicated for the adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer in patients who have received neoadjuvant chemoradiotherapy.